|Home | About | Journals | Submit | Contact Us | Français|
Embryonic hematopoiesis is a complex process. Elucidating the mechanism regulating hematopoietic differentiation from pluripotent stem cells would allow us to establish a strategy to efficiently generate hematopoietic cells. However, the mechanism governing the generation of hematopoietic progenitors from human embryonic stem cells (hESCs) remains unknown. Here, on the basis of the emergence of CD43+ hematopoietic cells from hemogenic endothelial (HE) cells, we demonstrated that VEGF was essential and sufficient, and that bFGF was synergistic with VEGF to specify the HE cells and the subsequent transition into CD43+ hematopoietic cells. Significantly, we identified TGFβ as a novel signal to regulate hematopoietic development, as the TGFβ inhibitor SB 431542 significantly promoted the transition from HE cells into CD43+ hematopoietic progenitor cells (HPCs) during hESC differentiation. By defining these critical signaling factors during hematopoietic differentiation, we can efficiently generate HPCs from hESCs. Our strategy could offer an in vitro model to study early human hematopoietic development.
Human embryonic stem cells (hESCs) and induced pluripotent stem (iPS) cells have unlimited proliferative capacity and are able to differentiate into multiple lineages, offering the promise of cell-replacement therapies for blood diseases. Previous studies have demonstrated that hESCs can differentiate into hematopoietic progenitor cells/stem cells (HPCs/HSCs) through the formation of embryoid bodies (EBs), or co-culture with hematopoiesis-supporting stromal cells, such as the OP9, S17 and AM20.1B4 cell lines 1, 2, 3, 4, 5. Recent studies have shown that iPS cells can also differentiate into HPCs 6, 7. However, these differentiation approaches have considerable drawbacks, such as being uncommitted and undefined, making them not optimal for studying the mechanisms of human hematopoietic development.
The establishment of a defined and stepwise strategy for generating hematopoietic cells from embryonic stem cells is valuable for the study of early hematopoietic development, and the EB strategy has been reported in the hematopoietic differentiation of mouse embryonic stem cells (mESCs) 8, 9, 10. In these systems, hematopoietic differentiation was generally divided into steps containing BRACHYURY+ embryonic primitive streak (PS), KDR+/Flk1+ mesoderm and CD41+ hematopoietic progenitor generation. Cytokines essential for the hematopoietic development were added to promote differentiation. A recent study also described a method to differentiate hematopoietic cells from hESCs in a defined medium 11. However, hematopoietic cytokines were administered throughout the entire process of differentiation, thus their precise effects on each developmental stage were less defined.
A reliable strategy to generate HSCs/HPCs from hESCs would be to recapitulate hematopoietic ontogeny based on a thorough understanding of the key signaling pathways controlling each developmental stage. Embryonic hematopoietic development is a complex process that involves a series of lineage specification precursors occurring at multiple anatomical sites within the embryo 12, 13. The first distinguishable embryogenic stage is the formation of the PS containing posterior and anterior parts that subsequently develop into the mesoderm and endoderm, respectively 14, 15. A subset of the early mesoderm in the posterior PS has the developmental potential to generate primitive and definitive hematopoietic cells 16. These hematopoiesis-potential mesoderm cells initiate primitive hematopoiesis after migrating to the yolk sac and can subsequently produce definitive hematopoietic cells 17, 18. The first definitive HSCs arise at the ventral wall of the dorsal aorta in the aorta-gonad-mesonephros (AGM) region 19, 20 and from murine and human placenta 21, 22, 23.
Recently, several studies have demonstrated that hemogenic endothelial (HE) cells are the direct precursors of HSCs; the most compelling evidence was obtained by tracing hematopoietic cell emergence in the AGM region of both zebrafish and mouse 24, 25, 26. Human early hematopoietic cells have also been shown to be generated from the blood-forming endothelium located in the embryonic aorta and vitelline artery 27, 28. A recent study described that the hematopoietic differentiation of mESCs occurred via a HE stage 29. During hESC differentiation, primitive endothelial cells with hemangioblastic properties have been shown to give rise to hematopoietic cells 30. In addition, hematopoietic progenitors expressing CD43 have been identified in the OP9 co-culture differentiation system 31. However, the mechanisms regulating the emergence of CD43+ HPCs from HE cells in vivo and in vitro have not been well studied.
In this study, we developed a stepwise hematopoietic differentiation strategy of hESCs by recapitulating embryonic hematopoiesis through the sequential stages of BRACHYURY+ PS/KDR+ early mesoderm induction, CD31+-enriched HE cell specification, CD43+CD45− hematopoietic cell emergence and CD43+CD45+ hematopoietic progenitor generation using a chemically defined strategy. On the basis of this strategy, we studied the mechanisms regulating the emergence of CD43+ HPCs from hESC-derived HE cells. We determined that TGFβ inhibition enhanced the generation of HPCs by combining with VEGF and bFGF, which allowed us to develop an efficient strategy to direct the differentiation of hESCs to HPCs.
Our previous work showed that the short-term treatment of hESCs cultured in a monolayer with BMP4 in a chemically defined medium (CDM) efficiently induced BRACHYURY- and KDR-expressing early mesoderm cells that possessed hematopoietic potential 32. On the basis of this differentiation system, we further induced the hematopoietic differentiation. We found that some differentiated CD31+ cells at day 4 with sheet morphology gradually generated non-adherent hematopoietic cells (Supplementary information, Figure S1A). This process was similar to the results from another study that hematopoietic cells were generated from mouse ESCs through HE cells with sheet morphology 29. Thus, we supposed that the CD31+ cells generated from hESCs contained HE cells. We further identified that these CD31+-enriched HE cells exhibited endothelial characteristics and had the potential to generate hematopoietic cells (Supplementary information, Figure S1B and S1C). In addition, we found that sorted CD31+ cells at day 5 could gradually undergo transition into CD43+ hematopoietic progenitors and that these CD43+ cells contained hematopoietic progenitors (Supplementary information, Figure S1D). Our results are consistent with previous studies 30, 31. On the basis of our identification of CD43+ HPCs arising from CD31+-enriched HE cells, we traced the entire hematopoietic differentiation process from hESCs using a flow cytometry analysis. We found that BRACHYURY+/KDR+ cells, CD31+ cells, CD43+ cells and CD45+ cells emerged sequentially during hematopoietic differentiation from hESCs (Figure 1A). Thus, we proposed a model to predict the entire process of the hematopoietic differentiation of hESCs that recapitulated the main stages of early hematopoietic development: (1) the commitment of BRACHYURY+/KDR+ PS/early mesoderm from hESCs; (2) the specification of HE cells expressing CD31 from the early mesoderm cells; (3) the emergence of CD31+CD43+CD45− hematopoietic cells from the HE cells; and (4) the generation of CD43+CD45+ HPCs from CD31+CD43+CD45− progenitors (Figure 1B). This differentiation method and the defined culture system allowed us to elucidate the mechanisms underlying each hematopoietic developmental step, particularly the critical step of hematopoietic cells emerging from HE cells.
Using our developed defined system, we first investigated the factors that regulate the HE cell specification from early mesoderm cells by testing various signaling factors that are involved in hematopoietic development (Supplementary information, Table S1). We added these factors to the differentiated cells after 2 days of treatment with activin A and BMP4, and then analyzed the generation of CD31+ cells at day 4. Surprisingly, we found that among the factors that we tested, only VEGF induced the generation of CD31+ cells (Figure 2A). We then examined the effects of the VEGF concentration on the generation of CD31+ cells and found a dose-dependent response within the tested concentration range (10-80 ng/ml; Supplementary information, Figure S2A, upper lane). We tested higher VEGF concentrations, but the generation of KDR+CD31+ cells was not increased (Supplementary information, Figure S2B). When combined with VEGF, bFGF showed a significant synergistic effect in inducing CD31+ cells (Figure 2B and and2C).2C). However, this effect of bFGF was abrogated when VEGF was added at high concentrations (40-80 ng/ml) (Supplementary information, Figure S2A, lower lane).
These VEGF-induced CD31+ cells transitioned into CD43+ hematopoietic progenitors upon further treatment with VEGF or VEGF + bFGF (Figure 2D), suggesting that VEGF is sufficient to specify HE cells enriched with CD31+ cells from the early mesoderm and it can further commit these HE cells into CD43+ HPCs. After further culturing these differentiated CD43+ cells in hematopoietic culture medium (HCM) containing SCF, TPO and IL3, CD45+ hematopoietic progenitors were generated (Figure 2E and and2F2F).
We further identified the factors that regulate the generation of CD43+ hematopoietic cells from hESC-derived HE cells by administering potential hematopoietic signaling activators or inhibitors (Supplementary information, Table S1) to day 4 differentiated cells, when CD43+ hematopoietic cells had not yet emerged (Figure 1A, the third lane). We detected CD31+CD43+ cells at day 6 generated in response to different treatments using a flow cytometry analysis. We found that VEGF, bFGF, TGFβ and retinoic acid (RA) signals regulated the transition of CD31+ cells into CD43+ hematopoietic cells (Figure 3A). VEGF was identified not only as an inducer to specify CD31+-enriched HE cells from the early mesoderm but also to further commit HE cells into CD43+ hematopoietic cells. The inhibition of bFGF using SU5402 almost completely inhibited the generation of CD43+ cells from HE cells, and the addition of bFGF to the HE cells enhanced the generation of hematopoietic cells from HE cells. These data suggested that bFGF played important roles in generating CD43+ hematopoietic cells from HE cells. Interestingly, we found that the TGFβ inhibitor SB431542 (SB) promoted the transition of CD31+ to CD43+ cells, while TGFβ1 completely inhibited the emergence of CD43+ cells (Figure 3A and and3B).3B). RA displayed a promoting effect, while its inhibitor LE540 completely abolished the emergence of CD43+ cells (Figure 3A and and3B).3B). We previously demonstrated a similar effect of RA on the hematopoietic differentiation of hESCs using the EB strategy 33. In addition, we found that SB and RA acted on CD31+ cells to enhance the transition of CD43+ cells from sorted CD31+ cells (Figure 3C and Supplementary information, Figure S3).
As SB was effective in enhancing the transition of CD43+ hematopoietic cells from HE cells, we further studied SB functions on hematopoiesis at different developmental stages. We administered SB from days 0-4 to the control condition that reflected 2 days of treatment with activin A + BMP4 and 4 days of treatment with VEGF + bFGF (VF). We tested the gene expression of differentiated cells with different treatments at day 6. When SB was added on the first day, the expression of mesoderm and hematopoietic genes including KDR, CD31, CD43, SCL, GATA 1, RUNX1, C-MYB, GATA2 and IKAROS was completely or mostly inhibited (Figure 4A). This result can be explained by the inhibitory effect of SB on activin A/nodal signal functioning at the first differentiation stage (data not shown). However, when SB was added at day 4, hematopoietic transcription factors, such as RUNX1, C-MYB, GATA 2, GATA 1, SCL, IKAROS and PU.1, were enhanced from two- to fivefold (Figure 4A). In addition, we found that the expressions of KDR and CD31 were not changed, but the expression of CD43 was enhanced (Figure 4A), suggesting that SB specifically enhanced hematopoietic differentiation at the step of the generation of hematopoietic cells from HE cells.
On the basis of a flow cytometry analysis, we found that SB treatment on day 4 enhanced the generation of CD43+ cells up to 35%-40%, while the differentiation efficiency was ~15%-20% in response to VF treatment (Figure 4B, upper lane). Significantly, the generation of CD43+CD235a− cells, which have been reported to enrich hematopoietic progenitors 30, was enhanced up to around 20% yield in response to VEGF + bFGF + SB (VFSB) treatment vs around 8% yield in response to VF treatment (Figure 4B, lower lane). Regarding the production of CD43+ cells from hESCs, VFSB treatment from days 4-6 enhanced the generation of CD43+ cells by two- to threefold compared with VF treatment (Figure 4D), although the total differentiated cell numbers were similar between these two groups (Figure 4C). We also found that SB exhibited similar effects in enhancing the generation of CD43+ cells during H9 differentiation (Supplementary information, Figure S4A). Therefore, these data suggested that SB acted in the hematopoiesis of hESCs, specifically at the stage in which CD43+ hematopoietic cells emerged from HE cells.
In contrast to the effect of SB, exogenous TGFβ1 decreased the generation of CD31+ cells and completely blocked the transition of CD43+ cells from CD31+ cells whenever it was added on day 2 or 4 (Figure 4E). In addition, we detected TGFβ1 expression in these differentiated cells generated in response to VEGF, bFGF and TGFβ1 (VFT), VF and VFSB treatments; the addition of TGFβ1 increased the endogenous TGFβ1 expression, while the addition of SB decreased the endogenous TGFβ1 expression (Supplementary information, Figure S4B). These data suggested that TGFβ1 had an inhibitory effect on hematopoietic differentiation and SB probably abrogated its inhibitory effect on hematopoietic cell generation.
We further studied these VFSB- and VF-induced hematopoietic cells by continuously culturing them in HCM containing SCF, TPO and IL3 in suspension. We found that VFSB-induced cells generated more CD43+CD45+ cells than VF-induced cells (~14% vs 4% at day 8, 38% vs 16% at day 12 and 50% vs 20% at day 18; Figure 5A-5C). When cells were further cultured to day 28, most of the VFSB-induced hematopoietic cells were viable and displayed proliferative abilities, whereas most of the VF-induced cells were dying (Figure 5D, right). Among these live cells, most of them expressed CD45 (Figure 5D, left).
In line with this result, VFSB-induced cells produced more hematopoietic colonies, including CFU-GM, CFU-G and CFU-mix, than VF-induced cells (Figure 5E and and5F).5F). In particular, after 28 days of culture, the VFSB-induced cells still generated CFU-E, CFU-G, CFU-M and CFU-GM colonies, but VF-induced cells lost that capacity (Figure 5G).
We also analyzed the globin expression of VF- and VFSB-induced cells at day 8 of differentiation. We found that the primitive globins, including -, γ- and ζ-globin, were expressed at similar level under these two conditions (Figure 5H, left). However, VFSB-generated hematopoietic cells expressed over twofold more β-globin than VF-induced hematopoietic cells (Figure 5H, right). In addition, we analyzed the β-globin expression of HPCs cultured in HCM containing EPO by a flow cytometry analysis and found that VFSB-generated HPCs produced nearly twofold β-globin-expressing erythrocytes than VF-generated HPCs (Figure 5I and Supplementary information, Data S1). All these results indicated that the inhibition of TGFβ by SB beginning at the HE cell stage enhances the generation of HPCs that are capable of sustaining proliferation in vitro for up to 1 month.
We next tested whether the enhanced hematopoiesis in response to SB resulted from the decreased apoptosis or enhanced proliferation of VFSB-induced hematopoietic cells. We evaluated Annexin V+ ratios among differentiated cells at days 5 and 6 and found ~10% decrease in Annexin V+ apoptotic cells in VFSB-induced cells compared with the VF-induced control (Figure 6A and and6C).6C). By further analyzing the apoptosis of CD31+ and CD31− cells generated with VF or VFSB treatment, we found that VFSB decreased the apoptosis ratio mainly in the CD31+ cells (Figure 6A). In addition, we analyzed the apoptosis of CD43+ cells generated from VF or VFSB conditions by co-staining CD43 with 7-AAD, we found that the ratio of VFSB-induced CD43+7-AAD+ cells was lower than that of VF-induced CD43+7-AAD+ cells (Figure 6B).
We assessed the proliferation rates of the differentiated cells by analyzing the percentages of Ki67+ cells in CD31+ and CD43+ cells. The results showed that Ki67+CD31+/CD31+ and Ki67+CD43+/CD43+ ratios showed no significant discrepancy between VFSB- and VF-induced CD31+ and CD43+ cells (Figure 6D). We counted the differentiated cells at day 6 and found that they expanded over 60-fold compared with the initiated hESCs, but there was no significant difference in expansion between VF- and VFSB-induced cells (Figure 4C). Our data supported that the enhanced hematopoiesis induced by SB probably results from the regulation of apoptosis but not from the regulation of the proliferation of hESC-derived hematopoietic cells.
After we defined the critical factors governing the generation of HE cells and HPCs and on the basis of previous studies 1, 5, 8, 9, 10, 11, 32, 33, we developed a four-step hematopoietic differentiation strategy of hESCs in a CDM. We treated hESCs with 50 ng/ml activin A and 50 ng/ml BMP4 for 2 days at the first stage, 40 ng/ml VEGF and 50 ng/ml bFGF for 2 days at the second stage, 40 ng/ml VEGF, 50 ng/ml bFGF and 20 μM SB for 2 days at the third stage and 50 ng/ml SCF, 50 ng/ml TPO and 50 ng/ml IL3 at the final stage (Figure 7A). This induction approach resulted in > 90% BRACHYURY+ PS cells in 2 days and > 90% KDR+ mesoderm cells and over 80% CD31+ cells in 5 days. Of these, nearly 40% of CD31+ cells transitioned into CD43+ hematopoietic cells on day 6, and > 90% cells differentiated into CD43+ hematopoietic cells on day 12. Finally, CD45+ HPCs were generated from ~60% of CD43+ cells by day 18 (Figure 7B).
In this study, we developed a novel stepwise strategy for inducing hESC differentiation in a CDM through sequential stages, including PS/early mesoderm induction, HE cell specification, hematopoietic cell emergence and hematopoietic progenitor generation. This strategy recapitulated the main embryonic hematopoietic development stages, as evaluated by determining the sequential onset of expression of BRACHYURY/KDR, CD31, CD43 and CD45. Thus, this strategy provided a reliable system to elucidate the signals regulating early hematopoietic development. Using this stepwise strategy, we identified critical signals regulating the generation of HE cells from hESC-derived early mesoderm cells and the transition from HE cells into HPCs in vitro. The elucidation of these crucial signals regulating early hematopoiesis makes it possible for us to efficiently generate HPCs from hESCs.
Among these differentiation stages, the step of CD43+CD45− hematopoietic cells emerging from HE cells would be the most critical during embryonic hematopoiesis in vivo and the hematopoietic differentiation in vitro. Recent progress has demonstrated that HSCs are originated directly from HE cells located in the AGM region during the embryogenesis 25, 26, 34. During the hematopoietic differentiation of mESCs, HE cells have been identified to directly generate CD41+ hematopoietic cells when mESCs are co-cultured with OP9 cells 29. A study of hESC hematopoietic differentiation has shown that primitive endothelial cells expressing CD31 have hemangioblastic properties and that these CD31+ cells further generated CD45+ hematopoietic progenitors 30. In addition, CD43 has been identified as the first marker expressed in hematopoietic progenitors and has been shown to discriminate hematopoietic cells from endothelial cells during hESC differentiation in vitro 30. Using a CDM, our study is the first report to recapitulate hematopoietic ontogeny in vitro through PS cell/early mesoderm induction, HE cell specification, CD43+ hematopoietic emergence and CD43+CD45+ hematopoietic progenitor generation (Figure 1A and and1B).1B). Among these steps, the step of CD43+ hematopoietic progenitor emergence from HE cells is probably the most critical point in determining the early hematopoietic fate. Therefore, our established accessible system for defining signals and uncovering new fate-determining factors regulating hematopoietic progenitor emergence will be valuable.
On the basis of the step of generating CD43+ HPCs from HE cells in our defined stepwise differentiation system, we identified that VEGF, bFGF, TGFβ inhibition and RA signals regulated the process of generating CD43+ cells from CD31+-enriched HE cells. In our study, VEGF was identified not only as an inducer of CD31+-enriched HE cells from early mesoderm cells but also to commit HE cells into hematopoietic progenitors. VEGF has been reported to play roles in the hematopoietic differentiation of hESCs in the EB system; however, VEGF was added throughout the differentiation process 11. Our study in a defined system identified that VEGF was essential and sufficient to specify CD31+-enriched HE cells from the early mesoderm, and also commit these HE cells into CD43+ hematopoietic progenitors (Figure 2). Therefore, our study clearly demonstrates the critical role of VEGF in the specification of HE cells and the generation of hematopoietic progenitors during hESC hematopoietic differentiation.
In this study, we identified TGFβ as a novel signal regulating the transition of CD43+ hematopoietic cells from HE cells. In our differentiation strategy, SB administration from day 4, when HE cells were generated, greatly enhanced the generation of CD43+ hematopoietic progenitors, hematopoietic gene expression and hematopoietic colony formation (Figures 3,,44,,5).5). Significantly, VFSB-induced HPCs had the capacity to survive and proliferate for 1 month of culture and still possessed the multilineage differentiation capacity (Figure 5D, ,5G)5G) to generate CFU-E, CFU-G, CFU-M and CFU-GM. Thus, the inhibition of TGFβ using SB greatly promotes hematopoiesis, particularly enhancing the generation of hematopoietic progenitors from hESC-derived HE cells. These effects probably resulted from the inhibition of endogenous TGFβ1 expressed by differentiated cells because exogenous TGFβ1 completely blocked hematopoietic progenitor emergence from HE cells (Figure 4E). It was reported that hematopoietic progenitors were generated through co-culture with AM20.1B4, which secreted TGFβ1 and TGFβ3 signals to regulate hematopoietic progenitor generation 3. The effects of TGFβ1 in the co-culture system are opposite from the results from our study. This difference could be due to the differences between the co-culture system and CDM. In line with our results, recent studies have shown that the inhibition of TGFβ using SB greatly enhances the generation of neural cells, hepatocytes and endothelial cells from human pluripotent stem cells, which may result from SB blocking the inhibitory effects of TGFβ on neural and hepatic differentiation 35, 36 and on endothelial expansion 37, 38.
In our study, we further evaluated the effects of SB on survival and proliferation using PI/Annexin V and Ki67, respectively (Figure 6). Our results demonstrated that SB did not affect proliferation rates compared with VF (Figure 6D), but decreased the apoptotic rates of human hESC-derived CD31+ cells and enhanced the gene expression of anti-apoptotic genes, such as BCL2, MDM2 and BAX (Supplementary information, Figure S5). Although SB decreased the CD43+7-AAD+ cells, the ratio of this population was low (Figure 6B). Therefore, these results suggested that SB enhanced the generation of HPCs from hESCs, probably through anti-apoptotic effects, and other mechanisms regulating the transition of CD43+ cells from HE cells may remain, which will be investigated in our future studies.
In summary, we have identified signals regulating the generation of HPCs from hESCs and developed a defined stepwise differentiation approach to efficiently produce hematopoietic progenitors from hESCs. This work provides a valuable model to study the signals regulating the generation of HPCs and will facilitate the future use of human pluripotent stem cells in the therapy of blood disorders.
H1 and H9 hES cell lines (Wicell Research Institute, Madison, WI, USA) were expanded on mitomycin C-treated primary mouse embryonic fibroblast cells in hESC culture medium consisting of DMEM/F12 supplemented with 20% knockout serum replacement, 1mM glutamax, 1% non-essential amino acids, 1% penicillin/streptomycin, 0.1 mM β-mercaptoethanol (all from Gibco, Grand Island, NY, USA), and 10 ng/ml human bFGF (Peprotech, Rocky Hill, NJ, USA) at 37 °C and 5% CO2 in a 100% humidified atmosphere incubator. Cells were split 1:3-1:5 every 5-7 days using 1 mg/ml dispase (Gibco).
For hematopoietic differentiation, 70%-80% confluent hESCs were treated with 1 mg/ml dispase (Gibco) for 5 min in a 37 °C incubator. Small scraped clumps were then collected and replated into Matrigel-pretreated (1:30 dilution; BD) 12-well or 24-well plates with hESC culture medium. The initial hESC density (1-2 × 105/well in 12-well plate) resulted in a low differentiation efficiency, while the improved density of ~0.5 × 105 cells/well in a 12-well plate resulted in higher hematopoietic differentiation efficiency. After overnight culture, hESCs were induced for stepwise differentiation under normoxic conditions. First, 50 ng/ml activin A and 50 ng/ml BMP4 or 50 ng/ml BMP4 and 50 ng/ml bFGF were added to the basic CDM of RPMI 1640 (Gibco) supplemented with 1 mM glutamax, 1% non-essential amino acids, 1% penicillin/streptomycin and 0.1 mM β-mercaptoethanol and 1% insulin-transferrin-selenium (ITS; Gibco). Second, VEGF and bFGF were added in CDM. Other factors tested at this stage are listed in Supplementary information, Table S1. Third, signal factors were added in CDM from days 4-6 as listed in Supplementary information, Table S1. Finally, differentiated cells at day 6 were resuspended in ultra-low attachment 24-well plates (Corning) and were cultured in HCM containing StemPro (Gibco), 1% penicillin/streptomycin, 1% ITS, 1 mM glutamax, 1% NAA, 1% penicillin/streptomycin, 2% B27 (all from Gibco), 0.1 mM MTG (Sigma), 50 ng/ml SCF, 50 ng/ml TPO and 50 ng/ml IL3. SCF, TPO and IL3 were purchased from Peprotech. Half of the medium was changed every 2 days.
Cells were trypsinized into single cells using 0.25% trypsin (Gibco) and resuspended in PBS containing 2% FBS. The cells were incubated with isotypic antibodies or the indicated antibodies for 30 min at 4 °C. Next, the cells were washed three times with PBS and suspended in 0.4 ml PBS for analysis. A total of 5 μl 7-AAD (BD Biosciences, San Jose, CA, USA) was added to each sample, and the samples were incubated for 5 min before analysis. Flow cytometry analysis was performed using FACS Calibur (BD Biosciences). The data were analyzed using Submit 4.0 (DakoCytomation, Fort Collins, CO, USA). The following antibodies were used: PE-BRACHYURY, APC-KDR, APC-TIE2 and PE-CD105 (R&D Systems) and PE-mouse IgG1, APC-mouse IgG1, FITC-mouse IgG1, PE-CD31, FITC-CD43, PE-CD34, APC-CD34, FITC-CD34, PE-CD45, APC-CD45, PE-PDGFRα, APC-C-KIT, APC-TIE2, APC-endoglin and APC-CD235a (BD Biosciences). For intracellular staining of BRACHYURY, the procedure was performed according to the manufacturer's instructions (R&D Systems).
Differentiated cells were dissociated using trypsin (From Gibco), resuspended in PBS with 2% FBS, filtered through a 40 μm cell strainer (BD Falcon, Franklin Lakes, NJ, USA) and resuspended in 300 μl of PBS containing 0.5% BSA. These cells were incubated with FITC-CD43 and PE-CD31 for 20 min at 4 °C, washed and sorted using a fluorescence-activated cell sorter (MoFlo). Differentiated cells were collected and stained using CD31 micro-beads (Miltenyi Biotec, Auburn, CA, USA) according to the manufacturer's instructions. The cells were suspended in PBS with 0.5% BSA and passed through a MS+ column (Miltenyi Biotec).
The total RNA of cultured cells was extracted using TRIzol (Invitrogen), and the total RNA of sorted cells was extracted using a micro-scale RNA isolation kit (RNAqueous-Micro, Ambion, TX, USA). Reverse transcription was performed according to the manufacturer's instructions (Promega, Madison, WI, USA). RNA expression levels were quantified using quantitative RT-PCR (Q-PCR). Q-PCR was performed using SYBR Green (Invitrogen). RNA levels were normalized using GAPDH as an internal control.
Single cells of the indicated numbers in 0.1 ml IMDM with 2% FBS were mixed with 1 ml MethoCult GF+ 4435 (Stemcell Technologies). The mixture was then transferred to 2 wells of ultra-low attachment 24-well plates (Corning). The cells were incubated at 37 °C in 5% CO2 with 100% humidity for 14 days, and the colonies were counted. Each type of colony was classified according to morphology. Each assay was performed in triplicate.
HESCs were differentiated using 2 days of treatment with activin A + BMP4 and 2 days of treatment with VEGF + bFGF and followed by VEGF + bFGF (VF) or VEGF + bFGF + SB (VFSB). The differentiated cells were trypsinized using trypsin without EDTA at days 5 and 6 and then analyzed using PI- and FITC-Annexin V staining (Xinbosheng Company, Beijing, China). Flow cytometry analysis was performed using FACS Calibur (BD Biosciences). The data were analyzed using Submit 4.0 (DakoCytomation). To examine apoptotic cells among CD43+ cells, we co-stained VF- and VFSB-treated differentiated cells with 7-AAD (BD Falcon). Flow cytometry analysis of CD43/7-AAD was performed using FACS Calibur (BD Biosciences), and the data were analyzed using Submit 4.0 (DakoCytomation).
To test the proliferation rates of differentiated cells, cells differentiated at day 5 and day 6 were collected and stained using a PE-CD31 antibody (BD) and a rabbit anti-human Ki67 primary antibody (Santa Cruz), followed by a FITC-conjugated mouse anti-rabbit secondary antibody (Santa Cruz). Flow cytometry analysis was performed using FACS Calibur (BD Biosciences). The data were analyzed using Submit 4.0 (DakoCytomation).
We thank Yizhe Zhang, Haisong Liu, Yan Shi, Hongxia Lv, Ting Liu and other colleagues in our laboratory for providing technical assistance and discussions in the preparation of this manuscript. This work was supported by grants from the Ministry of Science and Technology (2011DFA30730), the 111 project, the National Basic Research Program of China (973 program, 2011CB964800 and 2010CB945204) and the Bill & Melinda Gates Foundation (37871 to H Deng). This work was supported by a China Postdoctoral Science Foundation (20100319 to C Wang).
(Supplementary information is linked to the online version of the paper on the Cell Research website.)
(A) (i)Some CD31+ cells with sheet morphology gradually generated semi-adherent hematopoietic cells.
(A) Concentration effect of VEGF on CD31+ cells generation.
(A) SB 431542 enhances the generation of CD43+ hematopoietic cells from day-4 sorted CD31- cells but does not affect day-6 sorted CD31- cells.
(A) H9 cell line was differentiated at the third stage with VEGF and bFGF as control or with VEGF, bFGF and SB 431543 treatment for 2 days.
Gene expression analysis of differentiated cells at day 6 with VF and VFSB treatment from D4-D6.
Signal factors applied in the identification of signals regulating CD31+ HE generationand CD43+ hematopoietic emergence.
Materials and Methods